Pulse updates

Showing 13 results

April 2023

Pulse Update Apr 21, 2023
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®

March 2023

Pulse Update Mar 02, 2023
Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch

January 2023

Pulse Update Jan 09, 2023
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023

September 2021

Pulse Update Sep 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
Pulse Update Sep 03, 2021
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
Pulse Update Sep 02, 2021
Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee

August 2021

July 2021

June 2021

Share Post Share Whatsapp Linkedin Email